UK Non-invasive Prenatal Diagnostics Market Size & Outlook
Related Markets
UK non-invasive prenatal diagnostics market highlights
- The UK non-invasive prenatal diagnostics market generated a revenue of USD 114.4 million in 2020 and is expected to reach USD 229.1 million by 2027.
- The UK market is expected to grow at a CAGR of 10.4% from 2021 to 2027.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2020.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
Non-invasive prenatal diagnostics market data book summary
| Market revenue in 2020 | USD 114.4 million |
| Market revenue in 2027 | USD 229.1 million |
| Growth rate | 10.4% (CAGR from 2020 to 2027) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data | 2015 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, Myriad Genetics Inc, Roche, Qiagen NV, Labcorp Holdings Inc, Biora Therapeutics, Quest Diagnostics Inc, Medgene Labs |
Other key industry trends
- In terms of revenue, UK accounted for 3.4% of the global non-invasive prenatal diagnostics market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Europe, Germany non-invasive prenatal diagnostics market is projected to lead the regional market in terms of revenue in 2027.
- UK is the fastest growing regional market in Europe and is projected to reach USD 229.1 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-invasive Prenatal Diagnostics Market Scope
Non-invasive Prenatal Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Medgene Labs | View profile | 11-50 | Sioux Falls, South Dakota, United States, North America | https://medgenelabs.com |
| CooperSurgical | View profile | 501-1000 | Trumbull, Connecticut, United States, North America | http://www.coopersurgical.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | https://www.bioratherapeutics.com/ |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | https://www.centogene.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Natera Inc | View profile | 3293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | https://www.natera.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
UK non-invasive prenatal diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-invasive prenatal diagnostics market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 45.89% in 2020. Horizon Databook has segmented the UK non-invasive prenatal diagnostics market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2015 to 2027.
NIPT was first offered in the country in 2012. NIPT is approved by the UK Genetic Testing Network only for certain specific conditions. Only high risk pregnant women are offered NIPT, for example, women who have an indication or family history of abnormalities. Moreover, NIPT is a safer option when compared to invasive tests.
The growing demand for NIPT in the region can be attributed to the ease of making informed decisions post the test for management of pregnancy. In addition, in 2016, the UK National Screening Committee suggested an approach that pregnant women with over 1 in 150 having a chance of aneuploidy development should be offered NIPT.
Moreover, recent technological improvement in approvals is also driving the market growth. For instance, in 2019, the UK NSC approved the procurement of next-generation sequencing and microarray for provision of NIPT.
Reasons to subscribe to UK non-invasive prenatal diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK non-invasive prenatal diagnostics market databook
-
Our clientele includes a mix of non-invasive prenatal diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK non-invasive prenatal diagnostics market, including forecasts for subscribers. This country databook contains high-level insights into UK non-invasive prenatal diagnostics market from 2015 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
UK noninvasive prenatal diagnostics market size, by gestation period, 2015-2027 (US$M)
UK Non-invasive Prenatal Diagnostics Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
